rate in Medical Technology

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, in...

New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer

--In a First, Immunotherapy Works Against Neuroblastoma-- PHILADELPHIA, May 28 /PRNewswire-USNewswire/ -- A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

SEATTLE, Nov. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has published in the November 1, 2008 issue the results of a study authored by Samual Jacobs et al. investigating the use of short-course CHOP-R followe...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that a planned...

Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations

Infant Deaths Spur Hard-Hitting, System-Wide Hand Washing Campaign That Drives Culture Change, Saves Lives CHARLOTTE, N.C., Sept. 16 /PRNewswire/ -- Novant Health, one of the top 10 integrated health systems in the country, dramatically increased hand-washing compliance from ...

American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation

MONTPELLIER, France, September 1 /PRNewswire/ -- The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that dronedarone (Multaq(R)) significantly reduces mean 24 hour ventricular rate, on top of other rate...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

74 percent of patients achieved SVR 12 with 48-week boceprevir-based combination therapy High SVR 24 rate also reported for 28-week boceprevir arm KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported top-li...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment o...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., June 5 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin gadolinium (MG...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that have shown a high objective response rate in...

CPR Data Debriefing by Hospital Responders Improves CPR Performance and Increases Initial Survival Rate Following Cardiac Arrest

Study published in Archives of Internal Medicine supports use of Q-CPR(TM) technology to improve CPR quality ANDOVER, Mass., May 26 /PRNewswire-FirstCall/ -- Royal Philips Electronics (NYSE: PHG , AEX: PHI) today announced the results of a study confirming the benefit of usin...

Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants

Retrospective Chart Review in 10 Geographic Regions throughout the United States Presented at Pediatric Academic Societies (PAS) Annual Meeting HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the us...

Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma

Phase II study of investigational regimen demonstrates important role of radioimmunotherapy in converting partial remissions to complete remissions and inducing a high rate of molecular remissions SEATTLE, March 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: C...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...

OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial

NAPLES, Italy, Jan. 10 /PRNewswire/ -- Patients who received OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, had significantly fewer major cardiac adverse events (MACE) than patients who received Boston Scientific's TAXUS or Johnson & Johnson's CYPHER drug-eluting stents in ...

Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin

ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- A retrospective analysis of healthcare claims in more than 20,000 patients with type 2 diabetes from an integrated U.S. national managed care database found that the initiation of insulin therapy with insulin glargine was associated with a lower ...

Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response

Top Line Results of Phase II Study in Previous Nonresponders also Reported KENILWORTH, N.J., Oct. 18 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided an update on the clinical development program for boceprevir, its investigational oral hepatitis C protease inh...

Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer

- Largest Series of Patients with Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115-116, Starting at 12:15 on Monday 24th September 2007 BARCELONA, Spain, Sept. 24 /PRNewswire/ -- Ne...

Adult Smoking Rate Continues Downward Trend

People of lower income and education still smoke more and are less likely to quit OLYMPIA, Wash., Aug. 1 /PRNewswire-USNewswire/ -- A new survey by the Washington State Department of Health shows the number of adult smokers in the state is continuing to drop. Sinc...

Arizona Doctor Offers New Addiction Drug Treatment for Meth Addicts Showing More Than 60% Success Rate

Dr. Gregory Ellison, Director of Advanced Medical Center, Licensed to Administer PROMETA(R) PHOENIX, April 11 /PRNewswire/ -- With Arizona facing a critical crisis of methamphetamine use, Dr. Gregory Ellison, Director of Advanced Medical Center, has identified a very p...

ProtoKinetix's AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 - ProtoKinetix Inc. (OTCBB:PKTX) has just received the results of studies conducted by ITTEC Stem, Inc. at the University of Finland. These outstanding results using AAGP(TM) in the cryopreservation process for stem cells demonstrate the vi...

Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cance...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Results of Largest Randomized, Placebo-controlled Trial Ever Conducted in CTCL Presented at the American Society of Clinical Oncology CHICAGO, June 04, 2007 /PRNewswire/ -- Preliminary results of the largest randomized, placebo-controlled clinical trial ever conducted in patients with ...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

... to its patients through the addition of High Dose rate (HDR) brachytherapy. This latest advance in brachy...ide effects may be reduced. Unlike low dose rate brachytherapy treatment, HDR therapy can be delive...ead of several days that are required for low dose rate brachytherapy. Cancer Centers of North Carolina is...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...as no different from placebo. The overall drop out rate in the study was 25 percent. The drop out rate was 21 percent in the placebo group and 30 percent...atment due to somnolence or sedation. The drop out rate observed in this study is comparable to drop out r...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

... risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, initiation, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data fr...

2,500 Cases Completed With the Magnetic Irrigated Catheter

...d catheter since its commercial release. The clinical performance of the catheter in these cases has been exceptional. The major adverse cardiac event rate for magnetic procedures remains at 0.1% "The irrigated tip is a great asset for creating deep lesions in patients with ventricular tachycardias...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... by atherosclerosis, or the build-up of plaques along the arterial wall, is the greatest single killer of American women--40% of total deaths--and the rate of mortality is nearly as high for men. Atherosclerosis can lead to the blockage of arteries that commonly support the heart, brain, kidneys and extre...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...nfusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness. Tre...)) Technology. Using this technology increases the rate of dissolution and enables the formulation of an a...competition; economic conditions, such as interest rate and currency exchange...

Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window

...123 (62 percent) patients reflected acceptable outcomes. Approximately nine percent suffered a symptomatic brain hemorrhage and the overall mortality rate was 22 percent. When analyzing what factors were most closely associated with favorable outcomes, successful restoration of blood flow, younger age, ...

FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia

...half of the patients with bipolar disorder who recover in response to treatment experience recurrence two years later. Patients may experience a high rate of failure due to lack of efficacy or side effects, including metabolic side effects. Poor tolerability frequently leads to treatment discontinuation...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

...ed on estimates from the Centers for Disease Control and Prevention, New Jersey is among the states with the highest breast cancer incidence and death rate in the country. The study by Medco and Indiana University School of Medicine that was presented at the 2009 Annual Meeting of the American Soc...

European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK

... intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's s...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...em cells or early progenitor cells that can create new depots of cancer throughout the body. Data showed that the projected five-year survival rate is 54% at a median follow up of 4.5 years (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results are superior...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

...tudy, uterine bleeding was not statistically different from placebo and the rate of endometrial hyperplasia in doses being considered for therapeutic use wa...c relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

...stically significant relative to placebo using the MITT MMRM (p=0.046).The responders analysis for CGI-I (SCORE <=2) demonstrated a higher response rate (58%) for BCI-952 as compared to buspirone alone (38%) (p=0.063) and placebo (36%) (p=0.055). The QIDS SR16 demonstrated numerical improvement ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...istically significant difference; however, the subjective reported response rate components did not as compared to placebo. Although the ACR scores for the ...lood measurements of C-Reactive Protein (CRP) and Erythrocyte Sedimentation rate (ESR) Efficacy Results Treatment N of Pts ACR 20 ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...rall survival (OS), progression-free survival (PFS), the objective response rate (ORR), and to further evaluate the safety and tolerability of BSI-201 in co... a statistically and clinically significant improvement in clinical benefit rate (CBR), median progression-free survival (PFS) and OS, compared with G/C alo...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

... general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the costs of defending or resolving putative class action...